Emergent BioSolutions (ER4) Stock Overview
A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ER4 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Emergent BioSolutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.02 |
| 52 Week High | US$11.72 |
| 52 Week Low | US$3.81 |
| Beta | 2.34 |
| 1 Month Change | 29.92% |
| 3 Month Change | -30.59% |
| 1 Year Change | -27.76% |
| 3 Year Change | 30.12% |
| 5 Year Change | -89.69% |
| Change since IPO | -39.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| ER4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.7% | 0.8% | -1.8% |
| 1Y | -27.8% | -3.2% | 4.2% |
Return vs Industry: ER4 underperformed the German Biotechs industry which returned -4.9% over the past year.
Return vs Market: ER4 underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| ER4 volatility | |
|---|---|
| ER4 Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ER4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ER4's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 900 | Joe Papa | www.emergentbiosolutions.com |
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination.
Emergent BioSolutions Inc. Fundamentals Summary
| ER4 fundamental statistics | |
|---|---|
| Market cap | €275.48m |
| Earnings (TTM) | -€152.47m |
| Revenue (TTM) | €664.22m |
Is ER4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ER4 income statement (TTM) | |
|---|---|
| Revenue | US$770.20m |
| Cost of Revenue | US$381.70m |
| Gross Profit | US$388.50m |
| Other Expenses | US$565.30m |
| Earnings | -US$176.80m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.45 |
| Gross Margin | 50.44% |
| Net Profit Margin | -22.96% |
| Debt/Equity Ratio | 170.4% |
How did ER4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 02:56 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Emergent BioSolutions Inc. is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| James Molloy | Brean Capital Historical (Janney Montgomery) |
| Dana Flanders | Goldman Sachs |